Artículos de revistas sobre el tema "Leeds melanoma Cohort"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 48 mejores artículos de revistas para su investigación sobre el tema "Leeds melanoma Cohort".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Newton-Bishop, Julia A., Samantha Beswick, Juliette Randerson-Moor, Yu-Mei Chang, Paul Affleck, Faye Elliott, May Chan et al. "Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma". Journal of Clinical Oncology 27, n.º 32 (10 de noviembre de 2009): 5439–44. http://dx.doi.org/10.1200/jco.2009.22.1135.
Texto completoNewton Bishop, J. A., S. Beswick, J. Randerson-Moor, Y. Chang, P. Affleck, F. Elliott, D. Elder, J. Barrett y T. Bishop. "Serum vitamin D levels, VDR, and survival from melanoma". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): 9016. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9016.
Texto completoNewton‐Bishop, Julia A., John R. Davies, Faheem Latheef, Juliette Randerson‐Moor, May Chan, Jo Gascoyne, Saila Waseem, Susan Haynes, Charles O'Donovan y D. Timothy Bishop. "25‐Hydroxyvitamin D 2 /D 3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort". International Journal of Cancer 136, n.º 12 (13 de diciembre de 2014): 2890–99. http://dx.doi.org/10.1002/ijc.29334.
Texto completoEmran, Abdullah Al, Jérémie Nsengimana, Gaya Punnia-Moorthy, Ulf Schmitz, Stuart J. Gallagher, Julia Newton-Bishop, Jessamy C. Tiffen y Peter Hersey. "Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts". Cancers 12, n.º 8 (28 de julio de 2020): 2082. http://dx.doi.org/10.3390/cancers12082082.
Texto completoBoon, Ian S., Peter Bownes, Shirin Namini, Carolyn Richardson y Satiavani Ramasamy. "Implementation of high dose rate (HDR) skin brachytherapy using the Valencia applicator: Leeds Cancer Centre non-melanoma cohort". Clinical Oncology 31 (octubre de 2019): e15. http://dx.doi.org/10.1016/j.clon.2019.09.042.
Texto completoWang, Minyu, Soroor Zadeh, Angela Pizzolla, Kevin Thia, David E. Gyorki, Grant A. McArthur, Richard A. Scolyer et al. "Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation". Journal for ImmunoTherapy of Cancer 10, n.º 4 (abril de 2022): e004095. http://dx.doi.org/10.1136/jitc-2021-004095.
Texto completoHassel, Jessica Cecile, Heiko Smetak, Martin Salzmann, Matthias Haefner, Denise Bernhardt, Ingrid Hülsmeyer, Alexander Enk, Juergen Debus y Philipp Beckhove. "Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA)." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14104-e14104. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14104.
Texto completoShah, Hemali, Paul Feustel y Lindy Davis. "Survivorship care plans and adherence with surveillance schedule in patients with invasive melanoma." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): e24079-e24079. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e24079.
Texto completoMeador, Lydia, Hari Menon, Haiyan Cui, Denise J. Roe, David J. DiCaudo y Karen Taraszka Hastings. "Inflammation induces GILT expression in human melanoma". Journal of Immunology 200, n.º 1_Supplement (1 de mayo de 2018): 178.28. http://dx.doi.org/10.4049/jimmunol.200.supp.178.28.
Texto completoBrendlin, Andreas Stefan, Felix Peisen, Haidara Almansour, Saif Afat, Thomas Eigentler, Teresa Amaral, Sebastian Faby, Adria Font Calvarons, Konstantin Nikolaou y Ahmed E. Othman. "A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma". Journal for ImmunoTherapy of Cancer 9, n.º 11 (noviembre de 2021): e003261. http://dx.doi.org/10.1136/jitc-2021-003261.
Texto completoAmaro, Adriana, Michela Croce, Silvano Ferrini, Gaia Barisione, Marina Gualco, Patrizia Perri, Ulrich Pfeffer et al. "Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition". Cancers 12, n.º 6 (4 de junio de 2020): 1468. http://dx.doi.org/10.3390/cancers12061468.
Texto completoNarous, M., Z. Nugent, H. Singh y C. N. Bernstein. "A164 RISKS OF SKIN CANCERS PRE- AND POST-INFLAMMATORY BOWEL DISEASE DIAGNOSIS". Journal of the Canadian Association of Gastroenterology 5, Supplement_1 (21 de febrero de 2022): 42–43. http://dx.doi.org/10.1093/jcag/gwab049.163.
Texto completoKuan, Feng-Che, Chung-Sheng Shi y Meng-Hung Lin. "Correlation of BRAF genomic alterations with higher mutation burden and predictive response to immune checkpoint inhibitors among human malignancies." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e14589-e14589. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14589.
Texto completoKuan, Feng-Che, Chung-Sheng Shi y Meng-Hung Lin. "Correlation of BRAF genomic alterations with higher mutation burden and predictive response to immune checkpoint inhibitors among human malignancies." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e14589-e14589. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14589.
Texto completoChampiat, Stephane, Martin Wermke, Johann de Bono, Aurelien Marabelle, Christiane Jungels, Cécile Vicier, Norbert Vey et al. "Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): CT188. http://dx.doi.org/10.1158/1538-7445.am2022-ct188.
Texto completoGeorge, Thomas J., Ji-Hyun Lee, Peter Joel Hosein, David L. DeRemer, Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Sherise C. Rogers et al. "Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 3122. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3122.
Texto completoGeorge, Thomas J., Ji-Hyun Lee, Peter Joel Hosein, David L. DeRemer, Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Sherise C. Rogers et al. "Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 3122. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3122.
Texto completoBeasley, Georgia, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, Matthias Gromeier y April Salama. "302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (noviembre de 2020): A329. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0302.
Texto completoPark, Jong Chul, Hatem Soliman, Gerald Falchook, Taofeek Owonikoko, Anna Spreafico, Erminia Massarelli, Meredith McKean et al. "511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A542. http://dx.doi.org/10.1136/jitc-2021-sitc2021.511.
Texto completoBeasley, Georgia M., Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin-Ho Jung et al. "Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma". Journal for ImmunoTherapy of Cancer 9, n.º 4 (abril de 2021): e002203. http://dx.doi.org/10.1136/jitc-2020-002203.
Texto completoOwonikoko, Taofeek K., Justin C. Moser, Janet Yoon, Emily K. Slotkin, Afshin Dowlati, Vincent T. Ma, Maria Düring y Joen Sveistrup. "Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junio de 2023): TPS3162. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3162.
Texto completoRicart, A. D., M. Cooney, J. Sarantopoulos, J. Brell, K. W. Locke, R. E. Gammans, G. Medina, A. Zambito, A. W. Tolcher y S. C. Remick. "A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 3096. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3096.
Texto completoPollack, Megan, Allison Shayna Betof, Katherine Rappazzo, Ian Valentine, Zeynep Eroglu, Douglas Buckner Johnson y Alexander Noor Shoushtari. "Safety of resuming anti-PD-1 (aPD1) in patients (pts) with immune-related adverse events (irAEs) during combined anti-CTLA-4 (aCTLA4) and aPD1 in metastatic melanoma (MM)." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 9544. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9544.
Texto completoPortuguese, Andrew J., Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson y Evan T. Hall. "Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review". Journal of the National Comprehensive Cancer Network 20, n.º 4 (abril de 2022): 406–16. http://dx.doi.org/10.6004/jnccn.2022.7009.
Texto completoGreif, Philipp A., Sebastian H. Eck, Nikola Konstandin, Anna Benet-Pages, Annika Dufour, Anna Vetter, Henning Popp et al. "Identification of Recurring Tumor-Specific Somatic Mutations In Acute Myeloid Leukemia by Transcriptome Sequencing." Blood 116, n.º 21 (19 de noviembre de 2010): 1059. http://dx.doi.org/10.1182/blood.v116.21.1059.1059.
Texto completoBothwell, Mia, Aaron Cheng, Leyre Zubiri, Meghan Mooradian, Yevgeniy R. Semenov, Gayle C. Blouin, Erica Tavares et al. "Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 2655. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2655.
Texto completoBodei, Lisa, Petr Kavan, Moishe Liberman, Neil Taunk, Ur Metser, Daniel Juneau, Eileen Mary O'Reilly, Junsheng Ma, Richard Cioci y Albiruni Ryan Abdul Razak. "FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junio de 2023): TPS3161. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3161.
Texto completoPurroy, Noelia, Nicholas Durham, Marc Phillips, Maureen M. Hattersley, Lindsey Jung, Diwakar Davar, Dmitriy Zamarin, Tanner M. Johanns y Igor Puzanov. "Abstract CT218: First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): CT218. http://dx.doi.org/10.1158/1538-7445.am2022-ct218.
Texto completoCoupe, Nicholas, Ian B. Walters, Robert A. Kramer, Uzi Gileadi y Mark R. Middleton. "A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL)." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 2582. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2582.
Texto completoGiovannini, I., R. Agarinis, S. Cacioppo, S. Sacco, G. De Marchi, E. DI Poi, A. Zabotti, L. Quartuccio y S. De Vita. "AB0490 PREVALENCE OF RISK FACTORS FOR CARDIOVASCULAR EVENTS, MALIGNANCY OR THROMBOEMBOLIC EVENTS IN RHEUMATOID ARTHRITIS UNDER JAK INHIBITORS IN A REAL-LIFE MONOCENTRIC COHORT". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de mayo de 2023): 1439.2–1440. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5908.
Texto completoLowndes, S. A., A. Adams, A. Timms, M. Middleton, C. Hayward, S. D. Reich, A. P. Mazar y A. L. Harris. "Phase I study of ATN-224 in patients (pts) with advanced solid tumours". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 2065. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2065.
Texto completoKnorr, David, Jeffrey Ravetch, Gabriela D’Andrea, Linda Vahdat, Christopher Klebanoff y Mark Robson. "496 Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A528. http://dx.doi.org/10.1136/jitc-2021-sitc2021.496.
Texto completoHamid, Omid, Melissa L. Johnson, Jason Luke, Richard T. Maziarz, Jamie Merchan, Emerson E. Lim, Sandip P. Patel et al. "Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): CT187. http://dx.doi.org/10.1158/1538-7445.am2022-ct187.
Texto completoAllen, Ian Matthew, Yonina Robbie Murciano-Goroff, Leyre Zubiri, Qun Li, Michael Sang Hughes, Marko Velimirovic, Jacqueline N. Chu et al. "Flu vaccination rate of patients with severe immune-related adverse events." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e18234-e18234. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18234.
Texto completoFugere, Brad, Jim Zhongning Chen, Farah Mazahreh, Tyler Fugere, Liyan Mazahreh y A. Mazin Safar. "Weight loss (WL) as a predictive factor for immune oncology (IO)." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junio de 2023): e14528-e14528. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14528.
Texto completoChen, Szu-Ying, Ons Mamai y Rosemary Akhurst. "Abstract 3420: Tgfbm3b is a natural germline genetic variant that modifies anti-tumor responses to anti-PD-1 immunotherapy through its action on the tumor microenvironment". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 3420. http://dx.doi.org/10.1158/1538-7445.am2022-3420.
Texto completoChawla, Sant P., Victoria S. Chua, Erlinda M. Gordon, John Cini, Susan Dexter, Manual DaFonseca, Justus Bingham, Grantham W. Hogeland y Richard T. Kenney. "Abstract CT245: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): CT245. http://dx.doi.org/10.1158/1538-7445.am2023-ct245.
Texto completoCrespin, Athéna, Pierre-Alain Bandinelli, Clément Le Bescop, Renaud Buffet, Jean De Gunzburg, Fabien Vitry, Gérard Zalcman y Julie Cervesi. "278 Systematic review and meta-analysis evaluating the impact of antibiotic use on clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A301—A302. http://dx.doi.org/10.1136/jitc-2021-sitc2021.278.
Texto completoTogami, Katsuhiro, Sun Sook Chung, Vikas Madan, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee Kim et al. "Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis". Blood 136, Supplement 1 (5 de noviembre de 2020): 13–14. http://dx.doi.org/10.1182/blood-2020-137727.
Texto completoJain, Nitin, Alessandra Ferrajoli, Musa Yilmaz, Philip A. Thompson, Marina Konopleva, Michael R. Green, Deepa Sampath et al. "Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)". Blood 138, Supplement 1 (5 de noviembre de 2021): 2626. http://dx.doi.org/10.1182/blood-2021-154195.
Texto completoSeviiri, Mathias, Richard A. Scolyer, D. Timothy Bishop, Julia A. Newton-Bishop, Mark M. Iles, Serigne N. Lo, Johnathan R. Stretch et al. "Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting". Journal of Translational Medicine 20, n.º 1 (5 de septiembre de 2022). http://dx.doi.org/10.1186/s12967-022-03613-2.
Texto completoCastro, María Victoria, Gastón Alexis Barbero, María Belén Villanueva, Luca Grumolato, Jérémie Nsengimana, Julia Newton-Bishop, Edith Illescas, María Josefina Quezada y Pablo Lopez-Bergami. "ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation". Journal of Biomedical Science 28, n.º 1 (13 de noviembre de 2021). http://dx.doi.org/10.1186/s12929-021-00776-w.
Texto completoFarlow, Janice L., Scott A. McLean, Nithin Peddireddy, Carol R. Bradford, Kelly M. Malloy, Chaz L. Stucken, Kyle K. VanKoevering, Matthew E. Spector y Andrew J. Rosko. "Impact of Completion Lymphadenectomy on Quality of Life for Head and Neck Cutaneous Melanoma". Otolaryngology–Head and Neck Surgery, 20 de abril de 2021, 019459982110074. http://dx.doi.org/10.1177/01945998211007442.
Texto completoUrbanski, Alexander, Julia Minnemann, Cornelia Mauch, Thomas Schmidt, Nicole Kreuzberg, Max Schlaak, Christiane J. Bruns, Dirk L. Stippel y Roger Wahba. "Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis". Langenbeck's Archives of Surgery 408, n.º 1 (21 de enero de 2023). http://dx.doi.org/10.1007/s00423-023-02804-9.
Texto completoZhang, Wancong, Xuqi Xie, Zijian Huang, Xiaoping Zhong, Yang Liu, Kit-Leong Cheong, Jianda Zhou y Shijie Tang. "The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM". Frontiers in Immunology 13 (23 de septiembre de 2022). http://dx.doi.org/10.3389/fimmu.2022.919145.
Texto completoXu, Zhangling, Xia Lv, Wenwen Xu, Yan Ye, Xiaodong Wang, Shuang Ye, Huihua Ding y Wanlong Wu. "Spontaneous Intramuscular Hemorrhage in Anti-MDA5 Positive Dermatomyositis: A Case Series and Literature Review". Frontiers in Medicine 8 (24 de enero de 2022). http://dx.doi.org/10.3389/fmed.2021.802753.
Texto completoVereecke, Gertjan, Justine Defreyne, Dorien Van Saen, Sarah Collet, Jo Van Dorpe, Guy T'Sjoen y Ellen Goossens. "Characterisation of testicular function and spermatogenesis in transgender women". Human Reproduction, 30 de noviembre de 2020. http://dx.doi.org/10.1093/humrep/deaa254.
Texto completoPeleva, Emilia, Yue Chen, Hasan Rizvi, Catherine Harwood y Jun Wang. "010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)". British Journal of Dermatology 188, Supplement_4 (junio de 2023). http://dx.doi.org/10.1093/bjd/ljad113.010.
Texto completo